H-VLIYFTSSLHSGVPSR^-OH

Ref. 3D-PP48879

Informations sur le produit

• Nom: H-VLIYFTSSLHSGVPSR^-OH

Description

Peptide H-VLIYFTSSLHSGVPSR^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VLIYFTSSLHSGVPSR^-OH include the following: Direct and precise measurement of bevacizumab levels in human plasma based on controlled methionine oxidation and multiple reaction monitoring VP Gaspar, S Ibrahim, CA Sobsey - ACS Pharmacology & , 2020 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsptsci.0c00134 A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two R Legeron, F Xuereb , S Chaignepain - of Chromatography B, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1570023217302969 Development and validation of a method for airborne monoclonal antibodies to quantify workplace exposure LMH Reinders, D Noelle, MD Klassen, M Jaeger - of Pharmaceutical and , 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0731708522004678 Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices KAM de Jong, SJ van Breugel , MJX Hillebrand - Bioanalysis, 2020 - Future Sciencehttps://www.future-science.com/doi/abs/10.4155/bio-2020-0204 What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum? J Vialaret , S Broutin, C Pugnier, S Santele, A Jaffuel - Bioanalysis, 2018 - Future Sciencehttps://www.future-science.com/doi/abs/10.4155/bio-2018-0027 Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma HH Chiu , IL Tsai, YS Lu, CH Lin, CH Kuo - Analytical and bioanalytical , 2017 - Springerhttps://link.springer.com/article/10.1007/s00216-017-0607-0 Comparison of methods for quantitative analysis of ranibizumab and bevacizumab in human plasma using various bioanalytical techniques, including microfluidic CE DelGuidice, OA Ismaiel , WR Mylott Jr - of Pharmaceutical and , 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0731708522002448 Optimization and method validation for the quantitative analysis of a monoclonal antibody and its related fab fragment in human plasma after intravitreal administration CE DelGuidice, OA Ismaiel , WR Mylott Jr - of Chromatography B, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1570023220313507 Comparison of Methods for Quantitative Analysis of a Monoclonal Antibody and its Related Fab Fragment in Human Plasma Using Various Bioanalytical Techniques C DelGuidice, O Ismaiel , W Mylott - , Triple Quadrupole, and - papers.ssrn.comhttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=3999233 A fully validated LC"‘MS/MS method for quantifying bevacizumab in plasma samples from patients with NSCLC and its implications in therapeutic drug monitoring B Li, M Yang, X Wang, W Chen, H Lu - Oncology , 2024 - spandidos-publications.comhttps://www.spandidos-publications.com/10.3892/ol.2024.14356 A validated LC-MS/MS method for the quantification of bevacizumab in rat, cynomolgus monkey, and human serum A Zhou, J Yu, Y Wu, H Xue, D Zhong, X Diao - Journal of Pharmaceutical , 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S073170852300359X

• Marque: Biosynth